


Topical dorzolamide-timolol beneficial in neovascular AMD

26 February 2016



The researchers observed a decrease in mean central subfield thickness from 419.7 μm at enrollment to 334.1 μm at the final visit ($P = 0.01$). From enrollment to the last visit there was also a decrease in mean maximum subretinal fluid height (from 126.6 to 49.5 μm ; $P = 0.02$). From [enrollment](#) to the final visit there were nonsignificant decreases in the mean maximum pigment epithelial detachment height ($P = 0.12$) and the mean logMAR visual acuity ($P = 0.60$).

"These data suggest that topical dorzolamide-timolol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despite consistent, fixed-interval intravitreal anti-VEGF treatment for neovascular AMD," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

(HealthDay)—Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published online Feb. 25 in *JAMA Ophthalmology*.

Copyright © 2016 [HealthDay](#). All rights reserved.

Jayanth Sridhar, M.D., from the Thomas Jefferson University in Philadelphia, and colleagues conducted a prospective single-arm interventional study involving patients with neovascular AMD and persistent macular edema despite fixed-interval intravitreal anti-VEGF therapy. Ten patients (mean age, 78.2 years) with 10 affected eyes received a regimen of topical dorzolamide-timolol twice daily and the same intravitreal anti-VEGF therapy, administered at the same interval as before enrollment. Eight patients received intravitreal aflibercept and two received intravitreal ranibizumab.

APA citation: Topical dorzolamide-timolol beneficial in neovascular AMD (2016, February 26) retrieved 22 January 2022 from <https://medicalxpress.com/news/2016-02-topical-dorzolamide-timolol-beneficial-neovascular-amd.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.